临床实践中司美格鲁肽与替尔泊肽治疗2型糖尿病患者的心血管结局
该研究基于美国保险项目2018至2025年数据开展五项队列研究,采用倾向评分匹配平衡混杂因素,先在模拟SUSTAIN-6与SURPASS-CVOT试验中验证设计,再在扩展人群及头对头比较中评估替尔泊肽与司美格鲁肽的心血管有效性,结果支持两者在临床实践中心血管获益相当。
要点
- 在扩展人群中,司美格鲁肽对比西格列汀的心肌梗死或卒中复合结局风险比为0.82(95%CI 0.74至0.91)。
- 在扩展人群中,替尔泊肽对比度拉糖肽的含死亡复合结局风险比为0.87(95%CI 0.75至1.01)。
- 头对头比较中,替尔泊肽对比司美格鲁肽的风险比为1.06(95%CI 0.95至1.18)。
核心结论
- 这些发现支持替尔泊肽与司美格鲁肽在临床实践中心血管获益相当。
研究设计与样本
- 研究开展五项队列研究,纳入2018至2025年间参加美国保险项目、心血管风险升高(包括肥胖和2型糖尿病)的患者。
- 研究首先模拟SUSTAIN-6(司美格鲁肽对比西格列汀作为安慰剂替代)和SURPASS-CVOT(替尔泊肽对比度拉糖肽)以基准评估设计、数据和分析框架。
- 研究随后在反映临床实践中常见患者的扩展人群中评估每种药物,并直接比较替尔泊肽与司美格鲁肽。
- 基线混杂因素通过倾向评分匹配进行平衡。
主要发现
- 基准评估显示参考试验与其模拟在主要复合终点(心肌梗死、卒中或全因死亡)的所有单个终点上高度一致,但SUSTAIN-6的全因死亡除外。
- 在扩展人群中,司美格鲁肽对比西格列汀的心肌梗死或卒中复合结局风险比为0.82(95%CI 0.74至0.91)。
- 在扩展人群中,替尔泊肽对比度拉糖肽的含死亡复合结局风险比为0.87(95%CI 0.75至1.01)。
- 在替尔泊肽与司美格鲁肽的头对头比较中,风险比为1.06(95%CI 0.95至1.18)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cardiovascular outcome trials of the incretin-based medicines tirzepatide and semaglutide have shown benefits in populations with varying levels of cardiovascular risk. However, without direct head-to-head comparisons, treatment decisions rely on indirect evidence from heterogeneous trial populations, leaving optimal treatment choices uncertain. Here we conducted five cohort studies to assess the effectiveness of tirzepatide and semaglutide in patients with elevated cardiovascular risk, including obesity and type 2 diabetes, enrolled in insurance programs in the USA between 2018 and 2025. First, we emulated two cardiovascular outcome trials, SUSTAIN-6 (semaglutide versus sitagliptin as placebo proxy) and SURPASS-CVOT (tirzepatide versus dulaglutide), to benchmark and critically evaluate our design, data and analytic framework. Second, we assessed each drug in expanded populations reflective of patients routinely seen in clinical practice. Third, we directly compared tirzepatide versus semaglutide. Baseline confounders were balanced using propensity score matching. For the primary composite endpoint of myocardial infarction, stroke or all-cause mortality, benchmarking identified high agreement between the reference trials and their emulations for all individual endpoints except for all-cause mortality in SUSTAIN-6, informing subsequent analyses. In expanded populations, comparing semaglutide versus sitagliptin for the composite outcome of myocardial infarction or stroke yielded a hazard ratio of 0.82 (95% confidence interval (CI) 0.74 to 0.91), and comparing tirzepatide versus dulaglutide for the composite outcome including mortality yielded a hazard ratio of 0.87 (95% CI 0.75 to 1.01). In the head-to-head comparison of tirzepatide versus semaglutide, the hazard ratio was 1.06 (95% CI 0.95 to 1.18). These findings support a comparable cardiovascular benefit of tirzepatide and semaglutide in clinical practice and demonstrate how rigorously designed real-world evidence can complement randomized clinical trials. ClinicalTrials.gov registration: NCT06659744 , NCT07088718 , NCT07096063 .
引用
- Krüger N, Schneeweiss S, Desai RJ, et al. Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice. Nat Med. 2025. PMID: 41207920. doi:10.1038/s41591-025-04102-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。